SAN DIEGO (AP) – Apricus Biosciences Inc. said it is reconsidering its regulatory strategy for its foot fungus treatment MycoVa, indicating it may seek approval to market the drug for patients who don’t have athlete’s foot.
Apricus said a new analysis of its U.S. trials of MycoVa showed the drug worked in that smaller group of patients. Patients who have nail fungus and athlete’s foot have a higher risk of reinfection after treatment, Apricus said.
MycoVa combines terbinafine, a drug that is already approved as a treatment for nail fungus, with technology that causes the drug to be better absorbed by the skin. It was originally developed to treat nail fungus, but previous trials did not prove the drug is effective. Later trials conducted through a partnership with Novartis AG showed MycoVa worked as well as a current treatment.
Date: June 27, 2011
Source: Associated Press
Filed Under: Drug Discovery